MRI in patients with high-grade gliomas treated with bevacizumab and chemotherapy
Authors:
- 25 April 2006
- journal article
- Published by Wolters Kluwer Health in Neurology
- Vol. 66 (8) , 1258-1260
Abstract
Patients with recurrent gliomas (n = 14) were treated with bevacizumab and carboplatin, cpt-11, or etoposide. Follow-up MRI scans were obtained 2 to 6 weeks after initiation of treatment. Contrast-enhancing tumor shrank in 7 patients, with reductions evident in as little as 2 weeks after initiation of therapy. Treatment seemed more effective for heterogeneously enhancing tumor compared with solidly enhancing tumor.Keywords
This publication has 7 references indexed in Scilit:
- hERG1 channels are overexpressed in glioblastoma multiforme and modulate VEGF secretion in glioblastoma cell linesBritish Journal of Cancer, 2005
- Expression of VEGF and its receptors in different brain tumorsNeurological Research, 2005
- Dynamic Contrast-Enhanced and Diffusion MRI Show Rapid and Dramatic Changes in Tumor Microenvironment in Response to Inhibition of HIF-1α Using PX-478Neoplasia, 2005
- Antibody neutralization of vascular endothelial growth factor (VEGF) fails to attenuate vascular permeability and brain edema in experimental pneumococcal meningitisJournal of Neuroimmunology, 2005
- Role of the Vascular Endothelial Growth Factor Pathway in Tumor Growth and AngiogenesisJournal of Clinical Oncology, 2005
- Anti-VEGF antibody bevacizumab (Avastin) with 5FU/LV as third line treatment for colorectal cancerTechniques in Coloproctology, 2004
- MRI of high-grade glial tumors: correlation between the degree of contrast enhancement and the volume of surrounding edemaNeuroradiology, 1997